Jeffrey Cole, MD
Cardiovascular Disease · Baltimore, MDNPI 1548263908
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,158 and has fallen 85.2% since, to $171 in 2025.
Across 195 payments — averaging $13.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$529
- Amgen$295
- Boehringer Ingelheim$265
- Esperion Therapeutics, Inc.$187
- Johnson & Johnson$155
- Pfizer$153
- plus $1K from 21 others
Across 75 payments — averaging $65,572 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.7M
- Ionis Pharmaceuticals, Inc.$85K
- Amgen$62K
- Novartis$21K
- Genentech, Inc.$11K
- Esperion Therapeutics, Inc.$8K
What the payments were for
- Food & beverage$2,65399%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $529 |
| Amgen | 16 | $295 |
| Boehringer Ingelheim | 14 | $265 |
| Esperion Therapeutics, Inc. | 13 | $187 |
| Johnson & Johnson | 18 | $155 |
| Pfizer | 20 | $153 |
| Novo Nordisk | 7 | $134 |
| AstraZeneca | 8 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $97 |
| Amarin Pharma, Inc. | 5 | $83 |
| Actelion Pharmaceuticals US, Inc. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Kestra Medical Technology Services, Inc. | 1 | $63 |
| Gilead | 5 | $62 |
| Boston Scientific | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Merck | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Vivaquant Inc, Dba Rhythm Express | 5 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Bayer | 2 | $25 |
| Abbott | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $24 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Medtronic | 1 | $11 |
How this compares
$2,680 in reported general payments places this provider in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $506,732 |
| XareltoRivaroxaban | 112 | $118,648 |
| EntrestoSacubitril/Valsartan | 75 | $110,827 |
| JardianceEmpagliflozin | 45 | $57,645 |
| Repatha SureclickEvolocumab | 36 | $41,285 |
| BrilintaTicagrelor | 22 | $23,621 |
| Metoprolol Succinate | 489 | $9,264 |
| Ezetimibe | 208 | $8,695 |
| Atorvastatin Calcium | 473 | $7,953 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $5,589 |
| Rosuvastatin Calcium | 125 | $3,824 |
| Pravastatin Sodium | 102 | $3,632 |
| Clonidine | 15 | $3,331 |
| Carvedilol | 199 | $2,693 |
| ClopidogrelClopidogrel Bisulfate | 219 | $2,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $153 | $506,732373 claims |
| Johnson & JohnsonXarelto | $155 | $118,648112 claims |
| NovartisEntresto | $529 | $110,82775 claims |
| Boehringer IngelheimJardiance | $265 | $57,64545 claims |
| AstraZenecaBrilinta | $111 | $23,62122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Baltimore
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Charles CummingsBaltimore$114K
- John RickardBaltimore$109K
- Christopher DefilippiBaltimore$101K
- David KassBaltimore$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.